BridgeMD
Compares treatment options for Metastatic Cervical Cancer
Official title PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
ClinicalTrials.gov ID: NCT07472153
What this study is testing
What is PD-1 antibody?
PD-1 antibody is an investigational medicine, being studied as a potential treatment for metastatic cervical cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a randomized trial evaluating the results of using of PD-1 and PD-L1 immune checkpoint inhibitors combined with chemotherapy, with or without bevacizumab, in patients with metastatic, persistent, and recurrent cervical cancer.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75, women only
You may be able to join if
- Age ≥18-≤75 years.
- Histologically confirmed diagnosis.
- One of the forms of the cervical cancer:
- Metastatic cervical cancer (stage IVB according to FIGO (International Federation of Gynaecology and Obstetrics) 2018);
- Persistent cervical cancer (primary incurability after radical treatment for stages IIB-IVA cervical cancer according to FIGO 2018);
You likely can't join if
- Presence of another active malignant invasive neoplasm.
- Pregnancy or lactation period.
See the full eligibility criteria
- Age ≥18-≤75 years.
- Histologically confirmed diagnosis.
- One of the forms of the cervical cancer:
- Metastatic cervical cancer (stage IVB according to FIGO (International Federation of Gynaecology and Obstetrics) 2018);
- Persistent cervical cancer (primary incurability after radical treatment for stages IIB-IVA cervical cancer according to FIGO 2018);
- Reccurent cervical cancer (first recurrence after completed radical treatment for IA-IVB cervical cancer according to FIGO 2018).
- Availability of material for determining PD-L-1 expression for immunotherapy candidates.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- No contraindications to chemotherapy, immunotherapy, or bevacizumab.
- Signed informed consent to participate in the study.
- Presence of another active malignant invasive neoplasm.
- Pregnancy or lactation period.
The study team makes the final eligibility decision.
Where it's taking place
- Minsk, Lesnoy, Belarus
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Minsk, Lesnoy, Belarus. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.